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Abstract
Introduction
Atrial fibrillation is a common abnormal heart rhythm leading to 
increased thrombus formation and stroke risk.  Eckman (2016) states:
Atrial fibrillation (AF) is the most common significant cardiac rhythm 
disorder and is also the most powerful common risk factor for stroke: 
about 15% of all strokes in the U.S. are attributable to AF. (p. 234)
Vitamin K antagonists have long been used as an effective prophylactic 
medication to prevent thrombus formation in patients with atrial 
fibrillation.  According to Santarpia, Curcio, Sibilio, and Indolfi (2015), 
warfarin’s “effectiveness is proven by 64% relative risk reduction of 
stroke compared with placebo, and it also shows superior results to 
aspirin and to aspirin plus clopidogrel” (p. 914).  Warfarin, while 
effective at preventing thrombi, has several drawbacks associated with 
its use. The direct factor Xa inhibitors have been developed in an 
attempt to effectively anticoagulate patients while avoiding the negative 
aspects of warfarin.  
Research Questions




Direct factor Xa inhibitors are efficacious at preventing both ischemic and 
hemorrhagic stroke.  Apixaban is superior to warfarin in stroke prevention 
while rivaroxaban and edoxaban are non-inferior to warfarin.  All three 
direct factor Xa inhibitors cause less intracranial hemorrhage.  Apixaban 
had less bleeding risks associated with its use compared to warfarin.  
Rivaroxaban had similar bleeding rates as warfarin but increased 
gastrointestinal bleeding.  Edoxaban demonstrated less overall bleeding 
risk when compared to warfarin except increased gastrointestinal 
bleeding in the high-dose form.  No direct comparison studies of the 
direct factor Xa inhibitors have been performed.  Out of pocket costs of 
the direct factor Xa inhibitors is high, however, direct factor Xa inhibitors 
provided an overall cost savings with reduced number of strokes and 
intracranial hemorrhages.  The direct factor Xa inhibitors lack a reversal 
agent, however, the direct factor Xa inhibitors are associated with lower 
death rates when compared to warfarin.  
Atrial fibrillation is a common cause for stroke.  Vitamin K antagonists 
such as warfarin are an effective prophylactic medication to prevent 
stroke in patients with atrial fibrillation.  Warfarin, however, has a 
narrow therapeutic index, reacts with certain foods, increases bleeding 
risks, and requires frequent monitoring.  New medications have been 
developed to prevent clot formation while avoiding the negative effects 
of warfarin.  The purpose of this study was to compare direct factor Xa 
inhibitors (rivaroxaban, apixaban, and edoxaban) versus warfarin in 
stroke prevention, safety, and cost.
The review of literature analyzed studies comparing warfarin and direct 
factor Xa inhibitors in patients with atrial fibrillation. Study outcomes 
included stroke prevention, bleeding risks, and cost. Analysis on 
antidote/reversal agents were also examined.
Direct factor Xa inhibitors decreased stroke compared with warfarin 
with an odds reduction of 0.81 and decreased intracranial 
hemorrhages with an odds reduction of 0.56 (Bruins & Berge, 2013).  
Direct factor Xa inhibitors were more cost effective, but with higher out 
of pocket expense.  Direct factor Xa inhibitors have no reversal agent.  
Despite no antidote, research showed lower rates of fatal bleeding 
deaths associated with direct factor Xa inhibitor use compared to 
warfarin.
Cost:
• Amin et al. (2014) demonstrated cost savings with the direct factor Xa 
inhibitors apixaban ($493) and rivaroxaban ($358) for stroke prevention.  
In cost avoidance, excluding intracranial hemorrhage, apixaban saved 
$752 while rivaroxaban cost more than warfarin by $502.
• Out of pocket expenses depends on insurance coverage.  With no 
insurance the cost of rivaroxaban is $347 for 20 mg tabs, $342 for 5 mg 
apixaban tabs, and $290 for 60 mg edoxaban tabs.  The cost of warfarin 
is $13 for 5 mg tabs (Anticoagulants, 2015).
Reversibility:
• Despite no reversal agent Caldeira et al. (2015) completed a systematic 
review and meta-analysis comparing hemorrhage related deaths of the 
novel oral anticoagulants (NOACs) compared with warfarin.  Results 
demonstrated the NOACs had a 47% odds reduction for fatal bleeds in 
patients with atrial fibrillation (odds reduction, 0.53, 95% CI, 0.42-0.68, 
I2=0%, x2=3.85, Pheterogeneity=0.43).
• Granger et al. (2011) compared apixaban and warfarin in stroke 
prevention.  Results demonstrated 1.60% had stroke or systemic 
embolism on warfarin compared to 1.27% on apixaban (hazard ratio 
for apixaban, 0.79, 95% CI, 0.66-0.95, P<0.001 for noninferiority, 
P=0.01 for superiority).
• Patel et al. (2011) compared rivaroxaban and warfarin in stroke 
prevention.  Results demonstrated rivaroxaban had a stroke or 
systemic embolism occurrence rate of 1.7% per year compared to 
2.2% on warfarin (hazard ratio for rivaroxaban group, 0.79, 95% CI, 
0.66 to 0.96, P<0.001 for noninferiority).
• Giugliano et al. (2013) compared edoxaban and warfarin for stroke 
reduction and found high-dose edoxaban and warfarin had an equal 
ischemic stroke risk of 1.25% per year (hazard ratio 1.00, 95% CI, 
0.83 to 1.19, P<0.97).
Bleeding Risks:
• Bruins and Berge (2013) found factor Xa inhibitors decreased 
intracranial hemorrhage when compared to warfarin (odds ratio 0.51, 
95% CI, 0.41-0.64, I2=0%).  Factor Xa inhibitors decreased bleeding 
risks versus warfarin with high heterogeneity (odds ratio 0.89, 95% 
CI, 0.81-0.98, I2=81%).
• Miller, Grandi, Shimony, Filion, and Eisenberg (2012) demonstrated 
the new oral anticoagulants reduced rates of intracranial hemorrhage 
(RR, 0.49, 95% CI, 0.36-0.66).  Rivaroxaban had similar major 
bleeding risks while apixaban had less major bleeding risks when 
compared to warfarin (RR, 0.88, 95% CI, 0.71-1.09).  Rivaroxaban 
was associated with higher gastrointestinal bleeding (RR 1.46, 95% 
CI, 1.19-1.78).
• Giugliano et al. (2013) demonstrated warfarin had a major bleeding 
occurrence rate of 3.43% per year while 60 mg edoxaban had major 
bleeding occurrence rate of 2.75% per year (hazard ratio, 0.80, 95% 
CI, 0.71-0.91, P<0.001).  High-dose edoxaban was associated with 
higher rates of gastrointestinal bleeding (1.51% versus 1.23% in the 
warfarin group) (hazard ratio, 1.23, 95% CI, 1.02-1.50, P 
Value=0.03). 
• Direct factor Xa inhibitors are effective in preventing stroke and have 
similar or reduced bleeding risks when compared to warfarin.  Direct 
factor Xa inhibitors decrease the risk of intracranial hemorrhage.
• Direct factor Xa inhibitors have favorable pharmacokinetics and 
pharmacodynamics when compared to warfarin. 
• Cost is a major concern with out of pocket expenses of direct factor 
Xa inhibitors far exceeding that of warfarin.
• Despite no reversal agent, direct factor Xa inhibitors cause less 
bleeding deaths when compared with warfarin.  
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Statement of the Problem
Warfarin is an effective anticoagulant but has several drawbacks to its 
use including a narrow therapeutic index, reaction with foods 
containing vitamin K, variable pharmacokinetics/pharmacodynamics 
and increased risk of intracranial hemorrhage.  These factors led to the 
development of new medications such as the direct factor Xa inhibitors. 
References
Amin, A., Stokes, M., Makenbaeva, D., Wiederkehr, D., Wu, N., & Lawrence, J. H. (2014). Estimated medical
cost reductions associated with use of novel oral anticoagulants vs warfarin in a real-world non-valvular 
atrial fibrillation patient population. Journal of Medical Economics, 17(11), 771-781. 
doi:10.3111/13696998.2014.953682
Anticoagulants. (2015). Retrieved on 11-12-15 from http://www.goodrx.com/anticoagulants 
Bruins Slot KMH, & Berge, E. (2013). Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral
or systemic embolism in patients with atrial fibrillation. Cochrane Database of Systematic Reviews, 
2013(8), 1-89. doi:10.1002/14651858.CD008980.pub2
Caldeira, D., Rodrigues, F. B., Barra, M., Santos, A. T., de Abreu, D., Goncalves, N., . . . Costa, J. (2015). Non-
vitamin K antagonist oral anticoagulants and major bleeding-related fatality in patients with atrial fibrillation 
and venous thromboembolism: A systematic review and meta-analysis. Heart, 101(15), 1204-1211. 
doi:10.1136/heartjnl-2015-307489
Eckman, M. H. (2016). Decision-making about the use of non-vitamin K oral anticoagulant therapies for
patients with atrial fibrillation. Journal of Thrombosis and Thrombolysis, 41(2), 234-240. 
doi:10.1007/s11239-015-1276-5
Giugliano, R. P., Ruff, C. T., Braunwald, E., Murphy, S. A., Wiviott, S. D., Halperin, J. L., . . . Antman, E. M.
(2013). Edoxaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine, 
369(22), 2093-2104. doi:10.1056/NEJMoa1310907
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., . . . Wallentin, L.
(2011). Apixaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine, 
365(11), 981-992. doi:10.1056/NEJMoa1107039
Miller, C. S., Grandi, S. M., Shimony, A., Filion, K. B., & Eisenberg, M. J. (2012). Meta-analysis of efficacy and
safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial 
fibrillation. The American Journal of Cardiology, 110(3), 453-460. 
doi:http://dx.doi.org.ezproxy.undmedlibrary.org/10.1016/j.amjcard.2012.03.049
Papadakis, M. A., McPhee, S. J., & Rabow, M. W. (Eds.). (2015). Current medical diagnosis & treatment (54th
ed.). McGraw Hill Education.
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., . . . Califf, R. M. (2011). Rivaroxaban
versus warfarin in nonvalvular atrial fibrillation. New England Journal of Medicine, 365(10), 883-891. 
doi:10.1056/NEJMoa1009638
Santarpia, G., Curcio, A., Sibilio, G., & Indolfi, C. (2015). Clinical significance of non-vitamin K antagonist oral
anticoagulants in the management of atrial fibrillation. Circulation Journal: Official Journal of the Japanese 
Circulation Society, 79(5), 914-923. doi:10.1253/circj.CJ-15-0319
In patients with atrial fibrillation, do direct factor Xa inhibitors decrease 
the risk of stroke and bleeding, and are the direct factor Xa inhibitors 
cost effective when compared to warfarin?  Are direct factor Xa 
inhibitors reversible?
An online database search of 
PubMed and Cochrane was 
performed for scholarly 
articles related to direct 
factor Xa inhibitor use versus 
warfarin in nonvalvular atrial 
fibrillation.  Specific searches 
included efficacy of factor Xa 
inhibitors versus warfarin for 
stroke prevention, safety, 
cost, and reversibility. 
Atrial fibrillation is a risk 
factor for stroke and a 
commonly used grading 
scale to assess stroke risk in 
atrial fibrillation is the 
CHA2DS2-VASc score.
Stroke Prevention:
• Bruins and Berge (2013) 
completed a systematic 
review and found a 
statistically significant 
reduction of all types of 
strokes for the factor Xa 
inhibitors compared to 
warfarin (odds ratio 0.78, 
95% CI 0.69 to 0.89).
Santarpia et al., 2015, p. 917
Santarpia et al., 2015, p. 918
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